PROTECT Medication Associated with a Slower eGFR Decline in IgA Nephropathy Compared to Standard Care.

Published Date: 24 May 2024

Irbesartan and sparsentan have been linked to a slower decline in kidney function.

Read Full News

Latest News

Patient Perspective on Topical Steroid Withdrawal, With Briana Banos Briana Banos

Topical steroid withdrawal advocate Briana Banos urged clinicians to stay curious and treat patients as experts on their own bodies.

Corticosteroid Stewardship in Dermatology is Not Steroid Avoidance, With Adam Friedman, MD Adam Friedman, MD, FAAD

Friedman outlines how dermatologists can track cumulative corticosteroid exposure, identify at-risk patients, and improve patient adherence with handouts.

Q&A: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU

Q&A: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU

EADV 2026: Telikibart Attains EASI-75 in 70% at Week 16 in Atopic Dermatitis

EADV 2026: Telikibart Attains EASI-75 in 70% at Week 16 in Atopic Dermatitis

Tips for Clinicians Diagnosing Patients with Diverse Skin Types Mona Shahriari, MD, FAAD, Jennifer Soung, MD

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and why severity scores overlook dyspigmentation.

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

Todays Updates

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in Q3 2026

Phase 3 PROPEL Trial to Test Imeroprubart in Generalized Myasthenia Gravis Marco Meglio

PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.

This Week on NeurologyLive® — October 5, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Ecopipam Shows Early and Sustained Tic Reduction in New Pediatric Tourette Syndrome Analyses Louie Pasculli

New analyses from the D1AMOND clinical program found that 69.8% of participants achieved a clinically meaningful reduction in tic severity within 8 weeks of ecopipam treatment, while an interim 18-month analysis showed sustained improvement without new safety signals.

LRRK2 Inhibitor BIIB122 Fails to Slow Early-Stage Parkinson Disease Marco Meglio

Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.

Phase 1 Data Link ARV-102 LRRK2 Degradation to Oculomotor and CSF Biomarker Changes in Parkinson Disease Louie Pasculli

Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.

6 Nephrology Headlines You Missed in September 2026

6 Nephrology Headlines You Missed in September 2026

Todays Updates

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in Q3 2026

Phase 3 PROPEL Trial to Test Imeroprubart in Generalized Myasthenia Gravis Marco Meglio

PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.

This Week on NeurologyLive® — October 5, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Ecopipam Shows Early and Sustained Tic Reduction in New Pediatric Tourette Syndrome Analyses Louie Pasculli

New analyses from the D1AMOND clinical program found that 69.8% of participants achieved a clinically meaningful reduction in tic severity within 8 weeks of ecopipam treatment, while an interim 18-month analysis showed sustained improvement without new safety signals.

LRRK2 Inhibitor BIIB122 Fails to Slow Early-Stage Parkinson Disease Marco Meglio

Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.

Phase 1 Data Link ARV-102 LRRK2 Degradation to Oculomotor and CSF Biomarker Changes in Parkinson Disease Louie Pasculli

Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.

6 Nephrology Headlines You Missed in September 2026

6 Nephrology Headlines You Missed in September 2026

Latest News

Topical steroid withdrawal advocate Briana Banos urged clinicians to stay curious and treat patients as experts on their own bodies.

Friedman outlines how dermatologists can track cumulative corticosteroid exposure, identify at-risk patients, and improve patient adherence with handouts.

Q&A: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU

EADV 2026: Telikibart Attains EASI-75 in 70% at Week 16 in Atopic Dermatitis

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and why severity scores overlook dyspigmentation.

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

News All Time

Nail Detachment 4 Times More Common With GLP-1 Use

Nail Detachment 4 Times More Common With GLP-1 Use

Key Lessons in Leadership as a Clinician, With Kristina Duffin, MD Kristina Duffin, MD

Kristina Duffin, MD, MS, shares lessons from her LEADderm leadership session, including how to define which problems are truly yours to solve.

CUPID A and C: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU Tim Smith

Dupilumab improved overall CU-Q2oL scores and 22 of 23 items vs placebo at 24 weeks in omalizumab-naive CSU, per a pooled CUPID A and C analysis.

APEX Part B: Zumilokibart Achieves Primary Endpoint in Atopic Dermatitis Tim Smith

All 3 zumilokibart doses met the EASI-75 primary end point vs placebo at Week 16 in AbbVie's phase 2 APEX Part B atopic dermatitis study.

Climate Change Tied to Skin Disease Worsening in 42% of Countries

Climate Change Tied to Skin Disease Worsening in 42% of Countries

Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma

Intralesional BO-112 Attains 61% Response in Basal Cell Carcinoma

EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis

EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis

Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS

Tulisokibart Shows Phase 2b Efficacy in Moderate to Severe HS

The Present and Future of Precision Medicine in Dermatology, With Peter Lio, MD Peter Lio, MD

Peter Lio, MD, discusses why precision medicine has advanced further in psoriasis than atopic dermatitis, and what oncology can teach dermatology.

FDA Approves First Oral Treatment of Dermatomyositis in Adult Patients Tim Smith

The approval adds brepocitinib (Lisraya), an oral JAK/TYK2 inhibitor, as the first agent specifically studied and approved for dermatomyositis in adults.

Resilience in Medicine, HS Treatments, and the Oral JAK Pipeline Today Lisa A. Swanson, MD

Lisa Swanson, MD, on embracing failure in medicine and the oral JAK inhibitors advancing for hidradenitis suppurativa and alopecia areata.

How Failure Is the Stepping Stone to Success, With Lisa Swanson, MD Lisa A. Swanson, MD

Lisa Swanson, MD, on treating professional failure as a source of direction and resilience in her LEADderm 2026 talk.

Tips on Saying 'No' as a Dermatology Leader, With Adam Friedman, MD Adam Friedman, MD, FAAD

Adam Friedman, MD, discusses saying no strategically as a career skill in a LEADderm 2026 table talk on managing opportunities.

Competition, Burnout, and the Cost of Always Saying 'Yes' as a Clinician Adam Friedman, MD, FAAD

Adam Friedman, MD, traces dermatology's yes-first culture to residency competition, previewing an unrehearsed LEADderm 2026 negotiation exercise.

6 Dermatology Headlines You Missed in August 2026 Tim Smith

A roundup of dermatology's biggest August headlines, from an FDA approval to conference previews and conversations on equity in care.

Reaching Patients Online and Avoiding Burnout, With Steven Daveluy, MD Steven Daveluy, MD, FAAD

Steven Daveluy, MD, speaks on why dermatologists belong on social media, avoiding burnout in practice, and what excites him in HS treatment.

Recommended News For You

Doctors Remain Trusted Sources for Cancer Info in Post-Pandemic Era

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Talquetamab Combos Show Survival Benefit in r/r Myeloma

The Cherenkov color image shows the possibility of improving the quality of radiation therapy.

Video: How to treat kidney disease?

New target points to combination therapy for thwarting multidrug resistance in cancer treatment

Enzalutamide vs Abiraterone: Which is Better for mCSPC?

Recommended Articles For You

Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools 

Personalized Survivorship Navigation in Precision Cancer Care 

Prognostic Role of PLAU in Pan-Cancer and Neutrophil Infiltration in Bladder Cancer 

Evolution of Cancer Care Through Developmental Therapeutics 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How cancer misinformation exploits the way we think

2.

Traces of bacteria inside brain tumors may affect tumor behavior

3.

Tennessee Pharmacies Sell Potent Ivermectin Pushed by Anti-Vaccine Doctor

4.

Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial

5.

Prostate cancer relapse after radiotherapy is strongly predicted by biological markers.

1.

Exercise Programming in Cancer Recovery: Evidence-Based Strategies for Clinical Practice

2.

Demystifying Lymphocytes: Everything You Need to Know 

3.

Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments

4.

Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research

5.

Childhood Cancer Survivorship and Long-Term Organ Health

1.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

2.

International Conference on Innovations in Critical Care for Oncology and Cardiology

3.

International Symposium on Oncology, Cardiology and Critical Care Innovations

4.

International Conference on Cancer Nursing and Hematology Support

5.

International Conference on Clinical Medicine and Surgical Care

1.

How Nutrition Can Support Patients During Cancer Care

2.

Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion

3.

Navigating the Complexities of Ph Negative ALL - Part XIV

4.

An In-Depth Look At The Signs And Symptoms Of Lymphoma

5.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot